Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
June 27 : The FDA approved UCBs Rystiggo (rozanolixizumab), a subcutaneously administered humanized IgG4 monoclonal antibody, to treat generalized myasthenia gravis, a rare muscle-wasting autoimmune disease
Endocrine Connections, 6 (8), 647658
This shift is likely to drive higher demand for regular monitoring of glucose, lipids, liver, kidney, and cardiac parameters. Ameera Shah, Chairperson, Metropolis Healthcare | Q1 FY26 Dr Lal PathLabs is less convinced at least so far: Patient volume growth is partly a factor of the improved collection and lab network we have put in place
Hims & Hers Health Today HIMS Hims & Hers Health $30.85 +3.08 (+11.09%) As of 08/3/2026 03:59 PM Eastern This is a fair market value price provided by Massive
US$ 26.30
US$ 23.49
US$ 23.96
US$ 22.71
US$ 22.63
US$ 21.46
US$ 25.26
US$ 27.37
US$ 27.26
